EP Patent

EP1811986A1 — Gabapentin prodrug sustained release oral dosage forms

Assigned to XenoPort Inc · Expires 2007-08-01 · 19y expired

What this patent protects

Sustained release oral dosage forms of a gabapentin prodrug, 1 {[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl} 1 cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective…

USPTO Abstract

Sustained release oral dosage forms of a gabapentin prodrug, 1 {[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl} 1 cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.

Drugs covered by this patent

Patent Metadata

Patent number
EP1811986A1
Jurisdiction
EP
Classification
—
Expires
2007-08-01
Drug substance claim
No
Drug product claim
No
Assignee
XenoPort Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.